A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

Nature Communications

Volumn 7, Issue , 2016, Pages

  Schell, Michael J ^a,g   Yang, Mingli ^b   Teer, Jamie K ^a   Lo, Fang Yin ^c   Madan, Anup ^c   Coppola, Domenico ^a   Monteiro, Alvaro N A ^a   Nebozhyn, Michael V ^d   Yue, Binglin ^a   Loboda, Andrey ^d   Bien Willner, Gabriel A ^e   Greenawalt, Danielle M ^d   Yeatman, Timothy J ^b,f  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Gibbs Cancer Center   (United States)

^c LABORATORY CORPORATION OF AMERICA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Molecular Health   (United States)

^f XCENDA   (United States)

^g ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS18 PROTEIN; APC PROTEIN; B RAF KINASE; CBX4 PROTEIN; CONNECTIN; CSMD3 PROTEIN; FAM123B PROTEIN; FBXW7 PROTEIN; GNAS PROTEIN; HLA A ANTIGEN; ITGB4 PROTEIN; K RAS PROTEIN; LRP1B PROTEIN; MUCIN; MUCIN 16; MUCIN 4; OBSCURIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN P53; SMAD4 PROTEIN; SYNE1 PROTEIN; TAF1L PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 2; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; APC PROTEIN, HUMAN; BETA CATENIN; WNT PROTEIN;

CANCER; GENETIC ANALYSIS; GENOME; MOLECULAR ANALYSIS; MUTATION; SURVIVAL; TUMOR;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; EXOME; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MUTATION RATE; OVERALL SURVIVAL; SEQUENCE ANALYSIS; SURVIVAL RATE; CELL NUCLEUS; COLORECTAL TUMOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MUTATION; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STAINING; TUMOR GENE; WNT SIGNALING;

ADENOMATOUS POLYPOSIS COLI PROTEIN; BETA CATENIN; CELL NUCLEUS; COLORECTAL NEOPLASMS; GENES, NEOPLASM; HUMANS; KAPLAN-MEIER ESTIMATE; MICROSATELLITE INSTABILITY; MUTATION; MUTATION RATE; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STAINING AND LABELING; STATISTICS, NONPARAMETRIC; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84975034844     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11743     Document Type: Article

References (61)

1. Markowitz, S. D., Bertagnolli, M. M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449-2460 (2009).
2. Fearon, E. R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6, 479-507 (2011).
3. Dukes, C. Histological grading of rectal cancer: (section of pathology). Proc. R Soc. Med. 30, 371-376 (1937).
4. Domingo, E. et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J. Pathol. 229, 441-448 (2013).
5. De Sousa, E. M. F. et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19, 614-618 (2013).
6. Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619-625 (2013).
7. Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
8. Brocardo, M., Henderson, B. R. APC shuttling to the membrane, nucleus and beyond. Trends Cell Biol. 18, 587-596 (2008).
9. Jaiswal, A. S., Narayan, S. A novel function of adenomatous polyposis coli (APC) in regulating DNA repair. Cancer Lett. 271, 272-280 (2008).
10. Fearon, E. R., Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
11. Budinska, E. et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231, 63-76 (2013).
12. Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, prognostic value. PLoS Med. 10, e1001453 (2013).
13. Roepman, P. et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 134, 552-562 (2014).
14. De Roock, W. et al. Effects of KRAS, BRAF, NRAS, PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
15. Rodriguez-Bigas, M. A. et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J. Natl Cancer Inst. 89, 1758-1762 (1997).
16. Dry, J. R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264-2273 (2010).
17. Loboda, A. et al. EMT is the dominant program in human colon cancer. BMC Med. Genomics 4, 9 (2011).
18. Jass, J. R. et al. APC mutation and tumour budding in colorectal cancer. J. Clin. Pathol. 56, 69-73 (2003).
19. Salahshor, S. et al. Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosomes Cancer 26, 247-252 (1999).
20. Samowitz, W. S. et al. APC mutations and other genetic and epigenetic changes in colon cancer. Mol. Cancer Res. 5, 165-170 (2007).
21. Christie, M. et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis. Oncogene 32, 4675-4682 (2013).
22. Vilar, E., Gruber, S. B. Microsatellite instability in colorectal cancer-the stable evidence. Nat. Rev. 7, 153-162 (2010).
23. Boland, C. R., Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073-2087 e2073 (2010).
24. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283-4288 (2008).
25. Klaus, A., Birchmeier, W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 8, 387-398 (2008).
26. Fodde, R., Smits, R., Clevers, H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1, 55-67 (2001).
27. Albuquerque, C. et al. The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum. Mol. Genet. 11, 1549-1560 (2002).
28. Herbst, A. et al. Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/beta-catenin signaling. BMC Genomics 15, 74 (2014).
29. Schell, M. J. et al. A composite gene expression signature optimizes prediction of colorectal cancer metastasis and outcome. Clin. Cancer Res. 22, 734-745 (2016).
30. Thiel, A., Ristimaki, A. Toward a molecular classification of colorectal cancer: the role of BRAF. Front. Oncol. 3, 281 (2013).
31. Samowitz, W. S. et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65, 6063-6069 (2005).
32. Farina-Sarasqueta, A. et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann. Oncol. 21, 2396-2402 (2010).
33. Roth, A. D. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28, 466-474 (2010).
34. Ogino, S. et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin. Cancer Res. 18, 890-900 (2012).
35. Douillard, J. Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
36. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350-1356 (2015).
37. Conlin, A., Smith, G., Carey, F. A., Wolf, C. R., Steele, R. J. The prognostic significance of K-ras, p53, APC mutations in colorectal carcinoma. Gut. 54, 1283-1286 (2005).
38. Rowan, A. J. et al. APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'. Proc. Natl Acad. Sci. USA 97, 3352-3357 (2000).
39. Crabtree, M. et al. Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients. Oncogene 22, 4257-4265, 2003.
40. Therman, E., Susman, B., Denniston, C. The nonrandom participation of human acrocentric chromosomes in Robertsonian translocations. Ann. Hum. Genet. 53, 49-65 (1989).
41. Chen, J. et al. Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis 26, 37-43 (2005).
42. Hiltunen, M. O. et al. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int. J. Cancer 70, 644-648 (1997).
43. Sakamoto, Y., Kitazawa, R., Maeda, S., Kitazawa, S. Methylation of CpG loci in 5'-flanking region alters steady-state expression of adenomatous polyposis coli gene in colon cancer cell lines. J. Cell Biochem. 80, 415-423 (2001).
44. Segditsas, S. et al. Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp. Mol. Pathol. 85, 201-206 (2008).
45. Guo, Y. et al. Association of aberrant DNA methylation in Apc(min/\+) mice with the epithelial-mesenchymal transition and Wnt/beta-catenin pathways: genome-wide analysis using MeDIP-seq. Cell Biosci. 5, 24 (2015).
46. Rad, R. et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24, 15-29 (2013).
47. Jaiswal, A. S., Armas, M. L., Izumi, T., Strauss, P. R., Narayan, S. Adenomatous polyposis coli interacts with flap endonuclease 1 to block its nuclear entry and function. Neoplasia 14, 495-508 (2012).
48. Jaiswal, A. S., Balusu, R., Armas, M. L., Kundu, C. N., Narayan, S. Mechanism of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision repair. Biochemistry 45, 15903-15914 (2006).
49. Jaiswal, A. S., Narayan, S. Assembly of the base excision repair complex on abasic DNA and role of adenomatous polyposis coli on its functional activity. Biochemistry 50, 1901-1909 (2011).
50. Jaiswal, A. S. et al. Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. Neoplasia 15, 454-460, 2013.
51. Narayan, S., Jaiswal, A. S., Balusu, R. Tumor suppressor APC blocks DNA polymerase beta-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J. Biol. Chem. 280, 6942-6949 (2005).
52. Kim, R. et al. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS ONE 10, e0126670 (2015).
53. Li, H., Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
54. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
55. Wang, K., Li, M., Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
56. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
57. Giannakis, M. et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 46, 1264-1266 (2014).
58. Koo, B. K. et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665-669 (2012).
59. Loregger, A. et al. The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated beta-catenin by sequestering TCF4 to the nuclear membrane. Sci. Signal. 8, ra90 (2015).
60. Zebisch, M., Jones, E. Y. ZNRF3/RNF43-A direct linkage of extracellular recognition and E3 ligase activity to modulate cell surface signalling. Prog. Biophys. Mol. Biol. 118, 112-118 (2015).
61. Curia, M. C. et al. Transcript dosage effect in familial adenomatous polyposis: model offered by two kindreds with exon 9 APC gene mutations. Hum. Mutat. 11, 197-201 (1998).